HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight

Today's guest post comes from Stephen Hom, Co-Founder, EVP & Chief Operating Officer of RIS Rx. Drawing on RIS Rx's proprietary data and case studies, Stephen highlights patterns that can undermine patient support program effectiveness. He argues that a more data-driven approach can help manufacture

By Drug Channels · Jun 5, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered wi…
Jul 1, 2026
The WeekFierceBiotech ↗
QuantumCell has licensed AlzeCure Pharma's Alzheimer's disease platform and lead asset for $12 million upfront…
Jul 1, 2026
Orca Bio lands FDA nod for first-in-class Tregzi cell therapy
The WeekBriefing
FDA approved Orca Bio’s Tregzi, the first allogeneic regulatory T cell therapy for blood cancer patients needi…
Jul 1, 2026